Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - Sep 19, 2023 Form 4 Insider Report for RayzeBio, Inc. (RYZB)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
RYZB
Transactions as of
Sep 19, 2023
Transactions value $
$0
Form type
4
Date filed
9/19/2023, 08:41 PM
Previous filing
Sep 14, 2023
Next filing
Nov 16, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYZB Common Stock Conversion of derivative security +1.56M 1.56M Sep 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYZB Series D Preferred Stock Conversion of derivative security $0 -1.56M -100% $0.00* 0 Sep 19, 2023 Common Stock 1.56M Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date.